Cardiac remodeling following myocardial infarction is the initial myocardial hypertrophic response which follows myocardial injury and the eventual evolution to heart failure. Attenuation of the early adaptive hypertrophy can be translated into attenuation of heart failure response such that understanding the molecular and cellular mechanisms underlying progression of cardiac remodeling to heart failure is of crucial importance. Mitochondrial dysfunction is central to the loss of contractile function during ventricular remodeling/heart failure that are thought to be induced as a result of inactivation of cell signaling molecules, AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor (PPAR) coactivator-1alpha (PGC-1alpha). Mitochondrial permeability transition pore (MPTP) opening has been shown to be an end-effector for cell death that is associated with increased mitochondrial fragmentation due to alterations in the balance between fission and fusion of mitochondria. In this proposal, we hypothesize that the alterations in the AMPK/PGC-1alpha cascade trigger MPTP opening leading to cardiac dysfunction in post-infarction cardiac remodeling;modulation of the MPTP occurs through a direct interaction of AMPK/PGC-1alpha with the pore complex and/or indirectly, through AMPK-induced acetylation of cyclophilin D. To test our hypothesis we will study the intact heart, cultured cardiomyocytes and isolated mitochondria using an in vivo rat model of post-infarction remodeling and an in vitro model of rat cardiomyocyte hypertrophy. We have extensive experience with the proposed animal and cell models, and the necessary techniques to study mitochondrial function in cardiac diseases, and develop new pharmacological and conditional strategies for cardioprotection.
The specific aims of this proposal are to: (1) Examine whether progression of post-infarction remodeling to heart failure is associated with increased MPTP opening and mitochondrial fragmentation;(2) Determine whether MPTP formation is regulated by the AMPK/PPARalpha pathway in cardiac remodeling;(3) Define whether inhibition of MPTP has long-term protective effects during post-infarction remodeling. The proposed studies will identify the specific mitochondrial adaptations and alterations, and help develop new therapeutic strategies for treatment of post-myocardial infarction heart failure.

Public Health Relevance

The proposed studies are aimed at elucidating the mechanisms involved in mitochondria-mediated cardiac dysfunction with progression of post-infarction remodeling to heart failure. Particularly, the relationship between mitochondrial permeability transition pore (MPTP) opening/mitochondrial fragmentation and cardiac dysfunction will be investigated in an in vivo model of post-infarction cardiac remodeling and an in vitro model of cardiomyocyte hypertrophy. Since the mitochondria play a critical role in cell death through apoptosis and necrosis, prevention or reversal of MPTP opening is crucial to protect the heart against cardiac diseases. Therefore, the cardioprotective effects of the specific inhibitor for the main MPTP regulatory protein cyclophilin D, sanglifehrin A will be used in the present study to guard the heart against ventricular remodeling/heart failure.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Enhancement Award (SC1)
Project #
5SC1HL118669-02
Application #
8535195
Study Section
Special Emphasis Panel (ZGM1-MBRS-Y (SC))
Program Officer
Wong, Renee P
Project Start
2012-08-22
Project End
2017-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
2
Fiscal Year
2013
Total Cost
$241,237
Indirect Cost
$74,637
Name
University of Puerto Rico Med Sciences
Department
Physiology
Type
Schools of Medicine
DUNS #
948108063
City
San Juan
State
PR
Country
United States
Zip Code
00936
Javadov, Sabzali; Chapa-Dubocq, Xavier; Makarov, Vladimir (2018) Different approaches to modeling analysis of mitochondrial swelling. Mitochondrion 38:58-70
Parodi-Rullán, Rebecca M; Soto-Prado, Jadira; Vega-Lugo, Jesús et al. (2018) Divergent Effects of Cyclophilin-D Inhibition on the Female Rat Heart: Acute Versus Chronic Post-Myocardial Infarction. Cell Physiol Biochem 50:288-303
Parodi-Rullán, Rebecca M; Chapa-Dubocq, Xavier R; Javadov, Sabzali (2018) Acetylation of Mitochondrial Proteins in the Heart: The Role of SIRT3. Front Physiol 9:1094
Chapa-Dubocq, Xavier; Makarov, Vladimir; Javadov, Sabzali (2018) Simple kinetic model of mitochondrial swelling in cardiac cells. J Cell Physiol 233:5310-5321
Khuchua, Zaza; Glukhov, Aleksandr I; Strauss, Arnold W et al. (2018) Elucidating the Beneficial Role of PPAR Agonists in Cardiac Diseases. Int J Mol Sci 19:
Huang, Yan; Powers, Corey; Moore, Victoria et al. (2017) The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome. Orphanet J Rare Dis 12:49
Jang, Sehwan; Lewis, Taber S; Powers, Corey et al. (2017) Elucidating Mitochondrial Electron Transport Chain Supercomplexes in the Heart During Ischemia-Reperfusion. Antioxid Redox Signal 27:57-69
Parodi-Rullán, Rebecca M; Chapa-Dubocq, Xavier; Rullán, Pedro J et al. (2017) High Sensitivity of SIRT3 Deficient Hearts to Ischemia-Reperfusion Is Associated with Mitochondrial Abnormalities. Front Pharmacol 8:275
Javadov, Sabzali; Jang, Sehwan; Parodi-Rullán, Rebecca et al. (2017) Mitochondrial permeability transition in cardiac ischemia-reperfusion: whether cyclophilin D is a viable target for cardioprotection? Cell Mol Life Sci 74:2795-2813
Nuñez, Rebeca E; Javadov, Sabzali; Escobales, Nelson (2017) Angiotensin II-preconditioning is associated with increased PKC?/PKC? ratio and prosurvival kinases in mitochondria. Clin Exp Pharmacol Physiol 44:1201-1212

Showing the most recent 10 out of 28 publications